Are ponatinib and orebatinib equally effective?

Orebatinib has elicited encouraging responses and tolerability in patients with ponatinib-resistant chronic myeloid leukemia (CML), Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), and CML patients whose tumors have the T315I mutation. This treatment has been proven to be effective and safe, especially for patients resistant to ponatinib with the T315I mutation. The use of the new third-generation TKI orebatinibprovides a good safety profile for the Chinese CML and Ph-positive ALL patient groups.

Ponatinib is used to treat certain types of leukemia and belongs to a group of targeted therapy drugs called cancer growth inhibitors. Ponatinib blocks (inhibits) messages from proteins (kinases) that cause leukemia cells to grow. Orebatinib is a novel small molecule oral 3G BCR-ABL1 inhibitor. Orebatinib has good pharmacokinetic characteristics. This innovative TKI exhibits efficacy against wild-type and mutant BCR-abl 1 (IC50±0.5nM) and enhances cell cycle arrest and apoptosis in CML cells.

The original drug of Ponatinib has not yet been launched in China, so it is not included in the medical insurance. Domestic patients in need may only purchase it through overseas channels. The Hong Kong original version of Ponatinib specificationsThe price of 45mg*30 tablets per box may be around 40,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There are also generic ponatinib drugs produced in other countries, which are relatively cheap. The price of 45mg*30 tablets per box produced by Everest Pharmaceutical Factory in Bangladesh may be around 4,000 yuan (the price may fluctuate due to the exchange rate), and its drug ingredients are basically the same as those of the original drug.